Study on Niraparib Maintenance Treatment for Advanced Ovarian Cancer After Initial Chemotherapy Response

Inclusion Criteria

• Diagnosed with high-grade serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer at Stage III or IV.
• Have inoperable Stage III or IV cancer, or have had surgery and chemotherapy for Stage III or IV cancer.
• Completed 6 to 9 cycles of platinum-based chemotherapy, with at least 2 cycles after surgery.
• Achieved a complete or partial response to chemotherapy, with stable cancer marker levels.
• Must start the study within 12 weeks after the last chemotherapy cycle.
• Agree to undergo specific tumor testing.
• Women of childbearing potential must have a negative pregnancy test before starting the study.

Exclusion Criteria

• Have certain types of ovarian cancer, such as mucinous or clear cell subtypes.
• Have had complete removal of cancer with no visible disease after surgery.
• Have had more than two surgeries for the cancer.
• Are pregnant, breastfeeding, or planning to become pregnant during the study and for 180 days after.
• Have allergies to Niraparib or its ingredients.
• Have previously used PARP inhibitors or are receiving another maintenance treatment.
• Have received experimental treatments recently.
• Have severe blood cell issues from previous chemotherapy that lasted more than 4 weeks.
• Have conditions or treatments that could interfere with the study, such as recent blood transfusions or use of certain growth factors.
• Have had another invasive cancer diagnosed or treated within the last 5 years.